Table 1 The FDA-approved inhibitors for EGFR, other RTKs and KRAS for cancer treatments
Name | Target | Disease setting | Approval date |
|---|---|---|---|
Erlotinib (Tarceva) | EGFR-TK | Locally advanced or metastatic NSCLC; Pancreatic cancer | 2004 (NSCLC) |
2005 (Pan) | |||
Gefetinib (Iressa) | EGFR-TK | NSCLC with EGFR exon 19 deletions or exon 21 L858R mutation | 2015 |
Afatinib (Gilotrif®) | EGFR-TK | NSCLC with non-resistant EGFR | 2018 |
Osimertinib (Tagrissob®) | EGFR-TK | Metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutation | 2018 |
Mobocertinib (Exkivityâ„¢) | EGFR-TK (orally) | NSCLC with EGFR exon 20 insertions | 2021 |
Sunitinib (Sutent) | RTK | Gastrointestinal stromal tumor (GST), renal cell carcinoma (RCC), pancreatic cancer (Panc) | 2006 (GST; RCC) |
2011 (Pan) | |||
2017 (Recurrent RCC) | |||
Sorafenib (Nexavar) | RTK | Kidney, liver, and thyroid cancers | 2005 (RCC) |
2007 (HCC) | |||
2013 (Thyroid) | |||
Sotorasib (Lumakrasâ„¢) | KRASG12C | NSCLC with KRASG12C mutation | 2021 |